PROFOUND MEDICAL CORP (PRN.CA) Stock Fundamental Analysis
Canada - Toronto Stock Exchange - TSX:PRN - CA74319B5027 - Common Stock
9.3 CAD
+0.23 (+2.54%)
PRN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 16 industry peers in the Health Care Equipment & Supplies industry. PRN has a great financial health rating, but its profitability evaluates not so good. PRN is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
In the past year PRN has reported negative net income.
PRN had a negative operating cash flow in the past year.
In the past 5 years PRN always reported negative net income.
PRN had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -93.00%, PRN is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
PRN has a better Return On Equity (-122.40%) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93% | ||
| ROE | -122.4% | ||
| ROIC | N/A |
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRN's Gross Margin of 72.49% is amongst the best of the industry. PRN outperforms 93.75% of its industry peers.
In the last couple of years the Gross Margin of PRN has grown nicely.
The Profit Margin and Operating Margin are not available for PRN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
2. Health
2.1 Basic Checks
PRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRN has more shares outstanding
Compared to 5 years ago, PRN has more shares outstanding
The debt/assets ratio for PRN has been reduced compared to a year ago.
2.2 Solvency
PRN has an Altman-Z score of 0.70. This is a bad value and indicates that PRN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.70, PRN belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
There is no outstanding debt for PRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.7 |
ROIC/WACCN/A
WACC7.67%
2.3 Liquidity
PRN has a Current Ratio of 4.18. This indicates that PRN is financially healthy and has no problem in meeting its short term obligations.
PRN has a Current ratio of 4.18. This is amongst the best in the industry. PRN outperforms 100.00% of its industry peers.
A Quick Ratio of 3.34 indicates that PRN has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.34, PRN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.18 | ||
| Quick Ratio | 3.34 |
3. Growth
3.1 Past
The earnings per share for PRN have decreased by 0.00% in the last year.
Looking at the last year, PRN shows a very strong growth in Revenue. The Revenue has grown by 59.14%.
The Revenue has been growing by 20.67% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
Revenue 1Y (TTM)59.14%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%86.76%
3.2 Future
The Earnings Per Share is expected to grow by 23.32% on average over the next years. This is a very strong growth
PRN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 56.05% yearly.
EPS Next Y-32.56%
EPS Next 2Y3.06%
EPS Next 3Y13.53%
EPS Next 5Y23.32%
Revenue Next Year55.62%
Revenue Next 2Y82.09%
Revenue Next 3Y71.71%
Revenue Next 5Y56.05%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PRN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PRN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRN's earnings are expected to grow with 13.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.06%
EPS Next 3Y13.53%
5. Dividend
5.1 Amount
PRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:PRN (12/8/2025, 7:00:00 PM)
9.3
+0.23 (+2.54%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners41.02%
Inst Owner ChangeN/A
Ins Owners17.72%
Ins Owner ChangeN/A
Market Cap280.77M
Revenue(TTM)14.30M
Net Income(TTM)-39.34M
Analysts80
Price Target15.56 (67.31%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.31%
Min EPS beat(2)-40.1%
Max EPS beat(2)29.47%
EPS beat(4)2
Avg EPS beat(4)1.24%
Min EPS beat(4)-40.1%
Max EPS beat(4)42.88%
EPS beat(8)4
Avg EPS beat(8)-5.3%
EPS beat(12)7
Avg EPS beat(12)-2.31%
EPS beat(16)10
Avg EPS beat(16)0.34%
Revenue beat(2)1
Avg Revenue beat(2)-16.59%
Min Revenue beat(2)-38.03%
Max Revenue beat(2)4.86%
Revenue beat(4)1
Avg Revenue beat(4)-15.52%
Min Revenue beat(4)-38.03%
Max Revenue beat(4)4.86%
Revenue beat(8)2
Avg Revenue beat(8)-13.01%
Revenue beat(12)2
Avg Revenue beat(12)-18.46%
Revenue beat(16)3
Avg Revenue beat(16)-19.86%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)13.18%
EPS NQ rev (3m)21.68%
EPS NY rev (1m)5.16%
EPS NY rev (3m)1.18%
Revenue NQ rev (1m)6.3%
Revenue NQ rev (3m)1.95%
Revenue NY rev (1m)2.6%
Revenue NY rev (3m)2.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 6.33 | ||
| P/tB | 6.35 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.85
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.65
BVpS1.47
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -93% | ||
| ROE | -122.4% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 72.49% | ||
| FCFM | N/A |
ROA(3y)-49.72%
ROA(5y)-41.04%
ROE(3y)-64.26%
ROE(5y)-50.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.33%
GM growth 5Y2.85%
F-Score4
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.18 | ||
| Quick Ratio | 3.34 | ||
| Altman-Z | 0.7 |
F-Score4
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.58%
EPS Next Y-32.56%
EPS Next 2Y3.06%
EPS Next 3Y13.53%
EPS Next 5Y23.32%
Revenue 1Y (TTM)59.14%
Revenue growth 3Y15.83%
Revenue growth 5Y20.67%
Sales Q2Q%86.76%
Revenue Next Year55.62%
Revenue Next 2Y82.09%
Revenue Next 3Y71.71%
Revenue Next 5Y56.05%
EBIT growth 1Y-27.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.17%
EBIT Next 3Y20.88%
EBIT Next 5Y28.76%
FCF growth 1Y-71.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-71.34%
OCF growth 3YN/A
OCF growth 5YN/A
PROFOUND MEDICAL CORP / PRN.CA FAQ
What is the ChartMill fundamental rating of PROFOUND MEDICAL CORP (PRN.CA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to PRN.CA.
What is the valuation status for PRN stock?
ChartMill assigns a valuation rating of 0 / 10 to PROFOUND MEDICAL CORP (PRN.CA). This can be considered as Overvalued.
What is the profitability of PRN stock?
PROFOUND MEDICAL CORP (PRN.CA) has a profitability rating of 2 / 10.
What is the financial health of PROFOUND MEDICAL CORP (PRN.CA) stock?
The financial health rating of PROFOUND MEDICAL CORP (PRN.CA) is 7 / 10.